April 2026 in “Research Square” E13 fetal mouse fibroblast vesicles may help reduce scarring.
17 citations
,
January 2024 in “Burns & Trauma” The researchers reported that exosomes from hypoxic M2 macrophages, enriched with miR-26b-5p, promoted proliferation, migration, and invasion in human keloid fibroblasts through the PTEN-PI3K/AKT pathway, highlighting miR-26b-5p's role in keloid development.
28 citations
,
April 2023 in “Stem cell research & therapy” This study reviews the roles and mechanisms of MSC-derived exosomes in wound healing, noting their potential as promising cell-free therapies for cutaneous regeneration.
June 2026 in “Preprints.org” This review examines the mechanisms behind pathological scarring like hypertrophic scars and keloids, highlights the limitations of current treatments, and suggests that biomaterial-enabled delivery of anti-fibrotic statins, such as atorvastatin, may offer a promising therapeutic avenue for managing these scars.
December 2025 in “Nature Communications” This study demonstrated that skin organoids derived from human stem cells can model cutaneous tuberculosis, revealing that fibrosis development in Mycobacterium tuberculosis-infected organoids is linked to the PI3K-AKT and AP1 pathways in fibroblasts, and suggesting the potential for antifibrotic treatment evaluation.